According to in vivo experimental data, NP-conjugated FAL showed improved tumor-targeting efficiency and better tumor retention than those without conjugated peptide FAL, as shown in Figure 6B. The survival rate of the tumor-bearing mice and the tumor volume shown in Figure 6C,D demonstrate the enhanced antitumor effect by PTT/PDT achieved by the co-delivery of FAL-ICG-HAuNS and the FAL-Hb-loaded liposomes through ER-targeted immunogenic cancer death and relief of hypoxia in tumor lesions. Here, GSTM1 is linked to neoplasm.